Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06539195
PHASE2

DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)

Sponsor: Dizal Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study will treat patients with DLBCL whose disease comes back or is not responding to prior therapy. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.

Official title: A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

59

Start Date

2024-03-13

Completion Date

2026-12

Last Updated

2026-03-04

Healthy Volunteers

No

Interventions

DRUG

DZD8586

Daily dose of DZD8586 at 25 mg

DRUG

DZD8586

Daily dose of DZD8586 at 50 mg

DRUG

DZD8586

Daily dose of DZD8586 at 75 mg

Locations (14)

Research Site

Hefei, Anhui, China

Research Site

Beijing, Beijing Municipality, China

Research Site

Guangzhou, Guangdong, China

Research Site

Nanning, Guangxi, China

Research Site

Zhengzhou, Henan, China

Research Site

Wuhan, Hubei, China

Research Site

Changsha, Hunan, China

Research Site

Jinan, Shandong, China

Research Site

Linyi, Shandong, China

Research Site

Xi’an, Shanxi, China

Research Site

Chengdu, Sichuan, China

National Clinical Research Center for Blood Diseases, Blood Disease Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College

Tianjin, Tianjin Municipality, China

Research Site

Tianjin, Tianjin Municipality, China

Research Site

Hangzhou, Zhejiang, China